Want to see IN:BIOFILCHEM full AI Analyst Report?
BIOFILCHEM Stock Chart & Stats
₹31.98
₹0.75(2.34%)
At close: 4:00 PM EDT
₹31.98
₹0.75(2.34%)
Day’s Range― - ―
52-Week Range₹25.60 - ₹46.82
Previous CloseN/A
Volume6.29K
Average Volume (3M)1.37K
Market Cap
₹471.94M
Enterprise Value₹418.10M
Total Cash (Recent Filing)₹33.26M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)97.0
Beta1.48
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.30
Shares Outstanding16,273,800
10 Day Avg. Volume786
30 Day Avg. Volume1,370
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.95
Price to Sales (P/S)1.48
P/FCF Ratio-51.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageDebt remains modest relative to equity despite the 2026 increase, reducing balance-sheet strain and preserving financial flexibility. This gives the company more capacity to withstand operating volatility and potentially fund future needs without relying heavily on additional borrowing.
Growing Equity BaseA growing equity base strengthens the company’s underlying financial capacity and provides a broader cushion against weaker earnings or cash-flow periods. Combined with modest leverage, this can support resilience and leave management more flexibility in capital allocation.
Demonstrated Cash-Flow CapacityAlthough cash generation has since weakened, the strong positive operating and free cash flow reported in 2024 shows that the business has demonstrated an ability to convert operations into cash. That capability could support future recovery if cash-flow volatility moderates.
Bears Say
Revenue ContractionThe sharp 2026 revenue decline reduces visibility into demand and weakens the foundation for sustained earnings growth. A contraction after earlier expansion suggests that the company’s top-line performance is volatile, making capacity planning and durable profit improvement more difficult.
Margin CompressionVery thin gross and EBITDA margins leave limited room to absorb operating volatility or cost pressure. The deterioration from prior years also indicates that recent revenue has generated less operating profit, constraining internal reinvestment and making earnings more sensitive to small changes in performance.
Inconsistent Cash ConversionRepeated negative operating and free cash flow indicate that reported profitability has not consistently translated into cash. This weakens funding self-sufficiency, can increase reliance on balance-sheet resources, and makes sustained investment or debt reduction harder during weaker operating periods.
Biofil Chemicals & Pharmaceuticals Ltd. News
BIOFILCHEM FAQ
What was Biofil Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
Biofil Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹25.60 and its highest was ₹46.82 in the past 12 months.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s market cap?
Biofil Chemicals & Pharmaceuticals Ltd.’s market cap is ₹471.94M.
When is Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 12 days.
How were Biofil Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
Biofil Chemicals & Pharmaceuticals Ltd. released its earnings results on Aug 11, 2026. The company reported ₹0.067 earnings per share for the quarter.
Is Biofil Chemicals & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Biofil Chemicals & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Biofil Chemicals & Pharmaceuticals Ltd. pay dividends?
Biofil Chemicals & Pharmaceuticals Ltd. does not currently pay dividends.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biofil Chemicals & Pharmaceuticals Ltd. have?
Biofil Chemicals & Pharmaceuticals Ltd. has 16,273,800 shares outstanding.
What happened to Biofil Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
Biofil Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹0.067 in its last earnings report. Following the earnings report the stock price went down -1.061%.
Which hedge fund is a major shareholder of Biofil Chemicals & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:BIOFILCHEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofil Chemicals & Pharmaceuticals Ltd.
Biofil Chemicals and Pharmaceuticals Limited, headquartered in Indore, India, is primarily involved in the country's pharmaceutical and chemical industries. This company supplies a comprehensive array of fundamental drugs and chemical compounds, including sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride. Additionally, its product line features plastic dippers and caps. Beyond its product offerings, Biofil also provides contract manufacturing services for pharmaceutical items. The company was founded in 1985.
Technical Analysis
Krebs Biochemicals & Industries Ltd.
―
Lasa Supergenerics Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―